Iabetic cardiomyopathy: the look for a unifying hypothesis. Circ Res 2006, 98:596?05. 31. Teupe C, Rosak C: Diabetic cardiomyopathy and diastolic heart failure ?issues with relaxation. Diabetes Res Clin Pract 2012, 97:185?94. 32. Christopher CL, Mathuram LN, Genitta G, Cyrus I, Sundar SJ: O mega-3 polyunsaturated fatty acids inhibit the accumulation of PAS-positive material within the myocardium of STZ-diabetic wistar rats. Int J Cardiol 2003, 88:183?90. 33. Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, Mito S, Arozal W, Sukumaran V, Laksmanan AP, Soetikno V, Kodama M, Aizawa Y: Function of differential signaling pathways and oxidative anxiety in diabetic cardiomyopathy. Curr Cardiol Rev 2010, six:280?90. 34. Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, Coughlan MT, Cooper ME, Nguyen Television, Ritchie RH, Forbes JM: Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type2 diabetes.(S,S)-Ph-Bisbox Chemscene Free Radic Biol Med 2012, 52:716?23. 35. Wold LE, Ceylan-Isik AF, Ren J: Oxidative anxiety and anxiety signaling: menace of diabetic cardio myopathy. Acta Pharmacol Sin 2005, 26:908?17. 36. Dikalov S: Cross talk involving mitochondria and NADPH oxidases. Cost-free Radic Biol Med 2011, 51:1289?301.Li et al. Cardiovascular Diabetology 2014, 13:24 http://cardiab/content/13/1/Page 14 of37. Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008, 102:488?96. 38. Maisch B, Alter P, Pankuweit S: Diabetic cardiomyopathy-fact or fiction? Herz 2011, 36:102?15.Formula of 165894-37-1 39.PMID:24883330 Mashimo K, Sato S, Ohno Y: Chronic effects of ethanol on cultured myocardial cells: ultrastructural and morphometric studies. Virchows Arch 2003, 442:356?63. 40. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP: Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007, 115:909?17. 41. Gulick T, Cresci S, Caira T, Moore DD, Kelly KP: The peroxisome proliferator activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 1994, 91:11012?1016. 42. Falc -Pires I, Leite-Moreira AF: Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and therapy. Heart Fail Rev 2012, 17:325?44. 43. Sack MN: Kind two diabetes, mitochondrial biology plus the heart. J Mol Cell Cardiol 2009, 46:842?49. 44. Duncan JG: Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813, 2011:1351?359. 45. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks 3 pathways of hyperglycaemic damage. Nature 2000, 404:787?90. 46. Huynh K, McMullen JR, Julius TL, Tan JW, Like JE, Cemerlang N, Kiriazis H, Du XJ, Ritchie RH: Cardiac-specific insulin-like development aspect 1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction within a mouse model of diabetic cardiomyopathy. Diabetes 2010, 59:1512?520. 47. Hardie DG, John WS, David AP, Emma RH: Management of cellular energy by the AMP activated protein kinase system. FEBS Lett 2003, 546:113?20. 48. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient ener.